The Life Sciences team advised LifeMine Therapeutics on its completion of a $175 million Series C financing.
LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere.
New investors Invus and 3W Partners Capital participated in the financing; GlaxoSmithKline (GSK) also joined the round as a strategic partner. Existing investors, including GV, Arch Venture Partners, Blue Pool Capital and MRL Ventures Fund, also participated.
The Goodwin team was led by Kingsley Taft, Dan Hughes, Mulon Luo and William Ogden.
For more details, read the press release and articles in BioSpace and Boston Business Journal.